/
Oncology
Cutaneous Squamous Cell Carcinoma
15
Pipeline Programs↗
20
Active Trials↗
12
Companies Involved↗
Cutaneous Squamous Cell Carcinoma is an emerging landscape with 15 programs across 12 companies. The most active players are Merck & Co., Incyte, Sanofi. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 27
Approved
No programs
Analysis
Modality Breakdown
60%
Monoclonal antibody
6 of 10 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 93% of 15 pipeline programs.
Analysis
Trial Status
52
clinical trials
Completed13 · 25%
Recruiting10 · 19%
Withdrawn9 · 17%
Active, not recruiting7 · 13%
Unknown status5 · 10%
Terminated4 · 8%
Other4 · 8%
Clinical Trials
Trial Activity
52 trials
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Recruiting·—·Phase 1·NCT06664151·25 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)